UnknownPhase 2

Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?

Brazil17 participantsStarted 2022-09-26

Plain-language summary

The TODAY trial is a study to evaluate the efficacy and safety of topical oxybutynin deodorant for use in patients with axillary hyperhidrosis.

Who can participate

Age range

18 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged ≥18 years and ≤ 45 years * Not treated patient with another drug or treatment methodology for the disease for at least 30 days Exclusion Criteria: * Patients who are hypersensitive to oxybutynin hydrochloride. * Not treated patient with another drug or treatment methodology for the disease for at least 30 days * Patients who have menopausal symptoms * Patients who show signs of skin lesions in the armpit * Pregnancy. Women with the potential to bear children should be under contraceptive strategies and take a negative pregnancy test to be enrolled * Patients with COVID in the contagious phase (PCR+)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Improvement in hyperhidrosis severity by day 35, as measured by the Hyperhidrosis Disease Severity Scale (HDSS)

Timeframe: Baseline and Day 35

Quality of life (QoL) assessment using the improvement metrics from a quality-of-life questionnaire published in 2003: de Campos JR et al.

Timeframe: From randomization to end of study at Day 35

Trial details

NCT IDNCT05102396

SponsorSamantha Rodrigues Camargo Neves de Moura

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

Contact for this trial

Samantha Moura, MD

+55 11 5536-0109 samanthaneves74@gmail.com

View on ClinicalTrials.gov More Hyperhidrosis trials